title: Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS.
abstract: This trial examined the safety and possible MRI and clinical effects of anti-chlamydial antibiotic therapy in relapsing-remitting MS (RRMS). Newly diagnosed MS patients were selected to participate if they showed Chlamydia pneumoniae gene in their CSF and had one or more enhancing lesions on brain magnetic resonance imaging (MRI). After a 4-month run in phase of monthly MRI, patients were randomized to receive rifampin (300 mg twice daily) and azithromycin (500 mg every other day) for 6 months or placebo (PBO). Patients then had monthly MRI on therapy and two additional scans on months 12 and 14. Lumbar punctures were repeated between months 7 and 8 and within 2 weeks of termination of the study. Data on 4 patients on treatment and 4 on PBO were available for analysis. The primary outcome measure of showing a beneficial effect on enhancing lesions was not met. However, there was a significant difference in brain parenchymal fraction loss favoring those patient receiving antibiotics compared with PBO (p< or =0.02). Three of the four patients on antibiotic therapy cleared the organism from the CSF by month 12; in the PBO group one patient cleared the organism. The reduction in atrophy in patients receiving antibiotics must be viewed with caution, due to the small number of patients studied.
authors.affiliation: Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37212, USA. subramaniam.sriram@vanderbilt.edu
authors.forename: S
authors.initials: S
authors.lastname: Sriram
authors.forename: S Y
authors.initials: SY
authors.lastname: Yao
authors.forename: C
authors.initials: C
authors.lastname: Stratton
authors.forename: H
authors.initials: H
authors.lastname: Moses
authors.forename: P A
authors.initials: PA
authors.lastname: Narayana
authors.forename: J S
authors.initials: JS
authors.lastname: Wolinsky
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000473:pathology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000473:pathology*; D010865:Pilot Projects; D010919:Placebos; D012293:Rifampin / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D010919:Placebos; D017963:Azithromycin; D012293:Rifampin